SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

9777	Companies
195693	Keywords
126731	Articles
104058	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 07/15/2025 at 18:30, 6 months 15 days ago

Sanofi: Disclosure of trading in own shares
PRESS RELEASE

published on 06/30/2025 at 21:33, 7 months ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 06/30/2025 at 07:35, 7 months ago

Sanofi Releases Q2 2025 Aide Mémoire

Forward-looking Statements Investor Information Financial Modeling Aide Mémoire Sanofi Q2 2025
PRESS RELEASE

published on 06/30/2025 at 07:30, 7 months ago

Press release: Availability of the Q2 2025 Aide mémoire
Sanofi releases Q2 2025 Aide mémoire for financial modelling, to be published on July 31, 2025. Company details its commitment to innovation and impact in healthcare

Innovation Sanofi Aide Mémoire Financial Modelling Q2 2025
BRIEF

published on 06/25/2025 at 07:05, 7 months 5 days ago

Riliprubart Granted Orphan Drug Designation in the United States

FDA Immunology Orphan Drug Riliprubart Kidney Transplant
PRESS RELEASE

published on 06/25/2025 at 07:00, 7 months 5 days ago

Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
Sanofi's riliprubart granted orphan drug designation by FDA for antibody-mediated rejection in solid organ transplantation, addressing critical unmet need in transplant medicine

Orphan Drug Designation Sanofi Riliprubart Antibody-mediated Rejection Solid Organ Transplantation
BRIEF

published on 06/23/2025 at 07:05, 7 months 7 days ago

Sarclisa Gains EU Recommendation for Multiple Myeloma Treatment

Multiple Myeloma Phase 3 Study Sarclisa CHMP Approval Induction Therapy
PRESS RELEASE

published on 06/23/2025 at 07:00, 7 months 7 days ago

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
Sarclisa recommended for EU approval by CHMP for transplant-eligible newly diagnosed multiple myeloma based on GMMG-HD7 study. Potential to improve outcomes in frontline setting globally

Multiple Myeloma Sarclisa EU Approval GMMG-HD7 Study CHMP Recommendation
BRIEF

published on 06/20/2025 at 07:05, 7 months 10 days ago

FDA Approves Dupixent for Bullous Pemphigoid Treatment

FDA Approval Dupixent Type 2 Inflammation Bullous Pemphigoid Rare Skin Disease
PRESS RELEASE

published on 06/20/2025 at 07:00, 7 months 10 days ago

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
Dupixent approved in the US as the only targeted medicine for bullous pemphigoid, meeting the critical treatment needs of patients with uncontrolled disease

FDA Approval Chronic Disease Dupixent Type 2 Inflammation Bullous Pemphigoid

Accesswire

Published on 01/30/2026 at 23:00, 44 minutes ago

Avidian Gold Corp. Announces Director Resignation
Published on 01/30/2026 at 22:45, 59 minutes ago

Noram Lithium Announces Fully Allocated Non-Brokered Financing
Published on 01/30/2026 at 22:30, 1 hour 14 minutes ago

Alta Copper Receives Court Approval for Proposed Acquisition by Fortescue
Published on 01/30/2026 at 14:00, 9 hours 44 minutes ago

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 15 hours 9 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units

View all ACCESSWIRE

EQS Group

Published on 01/30/2026 at 22:00, 1 hour 44 minutes ago

Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 3 hours 34 minutes ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 20:09, 3 hours 35 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 20:07, 3 hours 37 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 19:13, 4 hours 31 minutes ago

Total Voting Rights

Les Echos

Published on 01/30/2026 at 17:45, 5 hours 59 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 15 hours 44 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 1 day 5 hours ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 5 hours ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 5 hours ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE